Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant

NCT05477108 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

108

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: Treatment A (BGF MDI HFO with oral activated charcoal)
DRUG: Treatment B (BGF MDI HFA with oral activated charcoal)

Sponsor

AstraZeneca

Collaborators

[object Object]